Background: Cervical cancer is the second most common cancer in women worldwide [1] . Photodynamic therapy has been used for cervical intraepithelial neoplasia with good responses, but few studies have used newer phototherapeutics. We evaluated the effectiveness of photodynamic therapy using Pc 4 in vitro and in vivo against human cervical cancer cells. Methods: CaSki and ME-180 cancer cells were grown as monolayers and spheroids. Cell growth and cytotoxicity were measured using a methylthiazol tetrazolium assay. Pc 4 cellular uptake and intracellular distribution were determined. For in vitro Pc 4 photodynamic therapy, cells were irradiated at 667 nm at a fluence of 2.5 J/cm 2 at 48 h. SCID mice were implanted with CaSki and ME-180 cells both subcutaneously and intracervically. Forty-eight hours after Pc 4 photodynamic therapy was administered at 75 and 150 J/cm 2 . Results: The IC 50 s for Pc 4 and Pc 4 photodynamic therapy for CaSki and ME-180 cells as monolayers were, 7.6 µM and 0.016 µM and >10 µM and 0.026 µM; as spheroids, IC 50 s of Pc 4 photodynamic therapy were, 0.26 µM and 0.01 µM. Pc 4 was taken up within cells and widely distributed in tumors and tissues. Intracervical photodynamic therapy resulted in tumor death, however mice died due to gastrointestinal toxicity. Photodynamic therapy resulted in subcutaneous tumor death and growth delay.
Introduction
Cervical cancer is the second most common cancer in women worldwide behind breast cancer [1] . In developing countries, cervical cancer is the most common cancer in women and the leading cause of cancer death [2] . In the United States, according to the American Cancer Society, there will be approximately 12,900 new cases and 4100 deaths in 2015 [3] . Cervical cancer can be categorized by extent of the spread of disease: localized tumors up to 4 cm are early stage disease; tumors larger than 4 cm or with paracervical involvement are locally advanced disease; involvement of other pelvic organs or distant metastases is advanced disease [4] . In the United States and Canada, concomitant chemoradiation is the standard of care for locally advanced disease and advanced disease, while neoadjuvant chemotherapy followed by radical surgery is used in Europe, Asia and Latin America [4] . Treatment of locally advanced disease with concomitant chemoradiation is often suboptimal and leaves approximately 40% of patients with residual disease [5] . There are limitations on the total radiation dose that can be administered so patients with persistent or recurrent disease after chemoradiation have few therapeutic options other than radical pelvic surgery that often entails removal of the rectum, bladder and vagina en bloc.
For cervical intraepithelial neoplasia (CIN), a preinvasive disease, the treatment is excisional or ablative therapy: LEEP (loop electrosurgical excision procedure), CKC (cold knife conization) or local destruction with either CO 2 laser or cryotherapy [6] . These excisional and ablative treatments can negatively impact the reproductive health of the women by potentially increasing the risk of preterm premature rupture of membranes and preterm labor [7] [8] [9] . There has been little progress in the last 20 years examining novel therapeutic modalities for CIN or cervical cancer.
Photodynamic therapy (PDT) is an attractive treatment modality for both preinvasive disease and invasive cervical cancer because its therapeutic agents, a photosensitizer, light and oxygen, are safe by themselves but lead to selective tumor destruction when combined. Advantages of PDT in the treatment of CIN and invasive cervical cancer include: the ability to localize treatment with the application of light; the sparing of intracellular matrix allowing regeneration of normal tissue; the potential for repetition of therapy without accumulation of toxicity; the potential of combining PDT with chemotherapy and, or radiation therapy to improve their efficacies; and the enhancement of antitumor immunity which may contribute to long term tumor control [8] [9] . Finally, PDT does not require anesthesia and generally does not cause bleeding which makes its use applicable to the outpatient setting.
The most widely used PDT therapeutics are Photofrin and various forms of 5-amino levulinic acid (ALA). Most recently, topical formulations of ALA have been used directly in the cervix with remission rates of 71%, 50% and 71% for CIN 1, 2 and 3 [8] . To date, PDT has not been used in the treatment of invasive cervical cancer.
Silicon phthalocyanine 4 (Pc 4) ( Figure 1 ) is a second generation photosensitizer developed at Case Western Reserve University in coordination with the Drug Decision Network of the National Cancer Institute. Among Pc 4's desirable features are: its chemical purity; its high extinction coefficient, 0.23 cm −1 µM −1 at 670 nm in aqueous solution, a wavelength allowing deep tissue penetration of light; and its rapid clearance from skin which limits the extent and duration of cutaneous photosensitivity after intravenous administration [10] [11] [12] . Pc 4 accumulates in the mitochondria, lysosomes and endoplasmic reticulum of the cells and Pc 4 PDT results in the generation of reactive oxygen species that result in both apoptosis and necrosis of cells exposed to
PDT. This effect of Pc 4 PDT has been demonstrated in numerous studies of cells in vitro [13] [14] [15] . Pc 4 PDT has also demonstrated promise in preclinical studies of Figure 1 . Structure and absorbance spectra of Pc 4 in 1× phosphate buffered saline.
squamous cell cancers of the head and neck, and has been used topically to treat cutaneous t-cell leukemia [14] [16] . In spite of its effectiveness and good safety profile in the Phase I clinical trial in cutaneous t-cell leukemia [16] , Pc 4 has not been evaluated in further clinical trials to date.
In this study, we evaluated the effectiveness of Pc 4 PDT in inhibiting the growth of human cervical cancer cells in vitro when grown as monolayers and spheroids, and in vivo. We measured the uptake of Pc 4 by the cells over time and the Pc 4 intracellular localization. We also examined the growth of cervical cancer cells when implanted in the cervix of immunodeficient mice and the uptake of Pc 4 by cervical cancer xenografts as well as other tissues after IV administration of Pc 4. We attempted intravaginal and subcutaneous delivery of irradiation after treatment of the mice with Pc 4. This preliminary data will be used to support further in vivo studies of Pc 4 PDT in the treatment of CIN and cervical cancer. 
Materials and Methods

Materials
Cell Culture
The human squamous cell carcinomas of the uterine cervix, CaSki and ME-180, were obtained from the American Type Culture Collection (CaSki:ATCC® CRL-1550™ and ME-180:ATCC® HTB-33™, Manassas, VA) and cultured in RPMI 1640 medium (Fisher Scientific) with L-glutamine, containing 10% fetal bovine serum, penicillin (100IU), streptomycin (100 µg/mL) and maintained in an incubator at 37˚C, 5% CO 2 and 95%
humidity. Monolayers were grown in standard 96-well flat bottom plates. Spheroids were created using Perfecta3D® Hanging Drop Plates (3D Biomatrix, Ann Arbor, MI) and were cultured on Corning™ Matrigel™ Membrane Matrix (Fisher Scientific) 1:1 with complete media.
Prevention of Phototoxicity
In order to prevent phototoxicity due to room lighting, cells removed from the incubator were processed in a vented laminar flow hood without lights and surrounded by green theatrical gels (Lee filter, 124) prior to and after introduction of Pc 4. Similarly, mice were housed in cages surrounded by these same theatrical gels 1 week following the administration of Pc 4 to prevent skin phototoxicity.
PDT in Vitro
Cells in logarithmic growth, 24 h after the addition of Pc 4, were irradiated through a microlens diffuser fiber (P/N5470RevD; 40 micron core, Pioneer Optics Co., Bloomfield, CT) on a diode laser (HPD 670 nm laser, 7404-D-EXT; High Power Devices, Inc., New Brunswick, NJ) at 670 nM. The laser was calibrated using a power meter (PM100;
Thorlabs, Newton, NJ). Fluence was maintained at 2. 
Cytotoxicity of Pc 4 and Pc 4 PDT in Cell Monolayers
CaSki cells or ME-180 cells (1 × 10 5 cells) in logarithmic growth were plated into each well of 96-well flat bottom, black sided culture plates and allowed to acclimate for 24 h. 
Cytotoxicity of Pc 4 and Pc 4 PDT in Spheroids
Spheroids of CaSki or ME-180 cells (1 × 10 4 cells) were prepared as described above.
The spheroids were allowed to attach for 24 h and Pc 4 was added at a final concentration of 1 nM-10 μM in medium containing 0.1% DMSO in every well under reduced lighting. After 24 h, the Pc 4 containing medium was removed; the spheroids were washed with PBS and new complete medium was added. The laser component (670 nm with a fluence of 2.5 J/cm 2 as described above) of PDT was administered to the spheroids. After 24 h, the spheroids were exposed to 1 mg/ml MTT for 4 h. The spheroids were then examined for the insoluble formazan using light microscopy and the percen- 
Pc 4 Uptake Studies
Monolayers or spheroids of CaSki or ME-180 cells were prepared as described above. After the addition of Pc 4, confocal images were collected at intervals between 3 and 9 h over a 36 h period using an inverted Zeiss 510 Meta confocal microscope. The spheroids were kept at 37˚C, 100% humidity and 5% CO 2 using a Tokai stage incubation chamber in the dark except for when confocal images were recorded.
Intracellular Distribution of Pc 4
CaSki and ME-180 cells were cultured on glass chamber-slides (Ibidi, µ-Slide 8 Well, 
Intracellular Organelle Markers for Endoplasmic Reticulum and Mitochondria
Expression plasmids containing ER or mitochondrial localized mCerulean3 were generously provided by Dr. Marcel Bruchez, Carnegie Mellon University [10] . The coding sequences from these plasmids were excised and inserted into a pENTR1A no ccdB
Gateway shuttle vector using the following restriction enzymes: for the ER construct, BamHI/XbaI; for the mitochondria construct, BamHI/XhoI. Using Gateway LR Clonase II (Life Technologies, Waltham, MA), the resulting plasmids were recombined with the pAd/CMV/V5-DEST Gateway Vector to produce pAd⁄CMV-DEST-ER and pAd/ CMV-Dest-Mitochondria, respectively. These constructs were then utilized to produce adenovirus using the ViraPower™ Adenoviral Gateway Expression Kit according to the manufacturer's recommendations (Life Technologies, Waltham, MA).
Animals and Tumor Model
Female C.B-17 SCID mice (specific pathogen-free, 4 -6 weeks of age) were purchased complete medium:matrigel) were implanted intracervically using a 27 g needle and 0.5 cc syringe. The injection was confirmed by the formation of a small weal at the site of injection. After injection the uterus, cervix, fat pads, and urinary bladder were returned to the peritoneal cavity. The peritoneum and musculature was sutured with dissolvable sutures (3 sutures using X-1, 22 mm 1/2 cm reverse cutting needle and 3 -0 coated vicryl plus antibacterial sutures, Ethicon Inc. Cincinnati, OH) and the skin was sealed with surgical staples that were removed on post-operative day 5 -7. Buprenorphine was administered twice daily for 2 days post-operatively for pain relief. Tumor volumes were estimated by palpation twice weekly beginning after staples were removed, and scored as +1 to +5 depending on the size of the tumors.
In the second model, CaSki or ME-180 cells were implanted subcutaneously on the right flank of mice (1 × 10 6 cells in 100 µl of complete medium).
Pc 4 in Plasma and Tissues by HPLC
When the intracervical tumors reached a score of +1 to +4 by palpation, the mice were 
PDT in Vivo
Five SCID mice bearing ME-180 cells implanted intracervically were used for intravaginal PDT. Additionally, one SCID mouse bearing CaSki cells and one SCID mouse bearing ME-180 cells implanted subcutaneously were also used. When the intracervical tumors reached an estimated 100 mm 3 based on palpation, the mice were administered Pc 4 at 2 mg/kg IV. Two days later, the mice were anesthetized with 50 mg/kg sodium pentobarbital. The mice were placed in the supine position on a platform and gently restrained so that the laser could be positioned intravaginally. The tumors were irradiated through a microlens diffuser fiber (P/N5470RevD; 400 micron core, Pioneer Optics Co., and delivered via two microlens fibers [16] . For the intracervical studies, the mice were administered 2 mg/kg Pc 4 48 h prior to irradiation and were restrained on their backs such that the laser was positioned to focus on the abdominal skin, on the tumor while reducing exposure to the gastrointestinal tract and liver. For the subcutaneous xenografts, mice were administered 2 mg/kg Pc 4 48 h prior to irradiation and were restrained on their left sides such that the laser was positioned to focus on the skin overlying their flanks.
Additional mice with either CaSki or ME-180 intracervical xenografts were imaged by PET CT every two weeks for three observations to measure the intracervical tumor spread. Mice were injected via tail vein with 1000 µCi 
Results
Growth and Cytotoxicity of Pc 4 and Pc 4 PDT in Monolayers
When CaSki cells and ME-180 cells were grown as monolayers, their doubling times were 56 and 25 h respectively (data not shown). Pc 4, added under reduced lighting was relatively non-toxic and its IC 50 in CaSki cells after 48 h of exposure was 7.6 µM, while after Pc 4 PDT, the IC 50 was 0.016 µM (Figure 2(a) ). ME-180 cells were less sensitive to Pc 4 and the IC 50 for Pc 4 alone was >10 µM. Higher concentrations of Pc 4 could not be evaluated because at higher concentrations the Pc 4 came out of solution in the medium. For ME-180 Pc 4 PDT, the IC 50 was similar to that of the CaSki cells, 0.026 µM (Figure 2(b) ). 
Cytotoxicity of Pc 4 and Pc 4 PDT in Spheroids
When CaSki cells and ME-180 cells were grown as spheroids, Pc 4 by itself was relatively non-toxic and its IC 50 for each cell line could not be calculated using concentrations up to 10 µM (Figures 3(a) and Figures 3(b) ). For Pc 4 PDT, the IC 50 in CaSki spheroids was much higher than had been observed in the CaSki cells grown as monolayers, 0.26 vs. 0.016 µM (Figure 3(a) ). In the case of ME-180 spheroids, the IC 50 was no higher than that of Pc 4 PDT for cells grown as monolayers (0.011 vs. 0.026 µM).
This difference in response to Pc 4 PDT between cell types in response may be due to the structure of the spheroids; the ME-180 spheroids are much less tightly packed as is seen in Figure 3 . The phase contrast images of insoluble formazan within the CaSki and ME-180 spheroids exposed to Pc 4 alone or after Pc 4 PDT are shown in Figure   3 (c) and Figure 3(d) . Because we could not extract the insoluble formazan from the spheroids using DMSO and a number of other solvents, we sectioned the spheroids at their largest diameter (~300 µm) to determine the depth of penetration of formazan and confirm that the viable spheroids contained formazan throughout. An ME-180 spheroid treated with Pc 4 only is shown in Figure 3 (e). As expected, there were no formazan crystals formed in the Pc 4 PDT treated spheroids beyond 0.1 µM Pc 4 in CaSki spheroids and beyond 0.01 µM in ME-180 spheroids.
Pc 4 Uptake in Monolayers
To confirm the uptake of Pc 4 in the CaSki and ME-180 cells, we measured both the concentration of Pc 4 in the medium and in the cells over time when the cells were continuously exposed to a Pc 4 concentration of 0.3 µM. As is apparent in Figure 4 (a) and 
Pc 4 Uptake in Spheroids
Pc 4 accumulated at a slower rate in these cervical cell lines when they were grown as spheroids on matrigel. The rate of accumulation into the spheroids is shown in Figure   4 (c) and Figure 4 (d), as fluorescence units (measured in confocal images taken at various times after addition of 0.3 µM Pc 4 at a depth of 105 µm into CaSki spheroids and a depth of 175 µm into the ME-180 spheroids). Uptake in CaSki spheroids was linear between 6 and 24 h, and then remained constant, while the uptake in the ME-180 spheroids continued to increase over the 35 h of exposure (Figure 4(e) ).
Intracellular Localization of Pc 4 in CaSki and ME-180 cells
Pc 4 was widely distributed within intracellular organelles with a similar distribution in both CaSki and ME-180 cells. Pc 4 could be found in the cytosol, lysosomes, endoplasmic reticulum and in the mitochondria of both cell lines ( Figure 5 ). In CaSki cells, the lysosomes appeared to show the most overlap between Pc 4 and the marker, followed by the endoplasmic reticulum; the mitochondria appeared to have less overlap between Pc 4 and the organelle marker ( Figure 5(a) ). A similar distribution was observed in the ME-180 cells grown as monolayers, but with more overlap between the mitochondrial marker and Pc 4 ( Figure 5(b) ).
Tumor Growth in Mice
In the mice after cervical implantation of either 1 × 10 5 CaSki or ME-180 cells, the tumors initially grew as small nodules in the cervix. As the disease progressed, however, it spread up the uterine horns and tumors were also localized as nodules attached to the peritoneal wall or mesentery. Several nodules were located attached to mesentery in peritoneal cavity just below the xypoid process. Select mice also had more advanced disease: metastases in liver parenchyma; or pelvic side wall disease eventually encasing the ureters and leading to post-renal obstruction. The tumors did not appear to spread dis-tally to affect the vagina or anus. In the SCID mice, the tumor growth was much slower for the CaSki implanted cells than for the ME-180 implanted cells; CaSki tumors reached a volume of 500 mm 3 by 8 -9 weeks while the ME-180 tumors reached similar volumes in only 4 -6 weeks as shown in Figure 7 (a) and Figure 7 (b).
Pc 4 Concentration in Xenografts and Normal Tissues
Four female SCID mice were implanted with CaSki cells and five with ME-180 cells subcutaneously on the right flank. One mouse bearing each xenograft was euthanized at 6, 24, 48 and 72 h after IV administration of Pc 4 at 2 mg/kg. One mouse bearing an ME-180 xenograft served as control. As is apparent in Table 1 1 Mice were implanted with ME-180 cells (1 × 10 5 cells/mouse intracervically) 7 weeks prior to Pc 4 (2 mg/kg IV).
Mice were euthanized at the times after Pc 4 administration indicated above; 2 NS is no sample; 
Pc 4 PDT in Vivo
Five mice with intracervical ME-180 xenografts were treated with intravaginal irradiation of the cervical tumors. Two mice were irradiated at 150 J/cm 2 and three were irra- CaSki intracervically implanted xenografts were euthanized nine days later to accurately measure the reduction in tumor volume, as presented in Figure 7 (c). The mice with ME-180 subcutaneously implanted xenografts were followed for tumor regrowth until 70 days after initial implantation. Pc 4 PDT was more effective in the subcutaneously implanted xenografts and regrowth of the tumors did not occur until two weeks after treatment, as presented in Figure 7 (d). The response to Pc 4 PDT of the ME-180 intracervically implanted xenografts was similar to the response of the CaSki intracervically implanted xenografts. Likewise, the response to Pc 4 PDT of the CaSki subcutaneously implanted xenografts was similar to the response of the ME-180 subcutaneously implanted xenografts (data not shown).
Discussion
In this study we have evaluated the use of a second generation phototherapeutic in the treatment of cervical cancer. For both the in vitro and in vivo studies presented here, we chose cell lines that would represent the HPV status of most cervical cancers. Both
CaSki and ME-180 uterine cervical cancer cell lines are epithelial in origin and were de- DNA of the high risk HPV types (HPV 16, 18 and 39) which are considered to be carcinogenic and are associated with the development of cervical cancer. HPV types 16 and 18 as well as 45, 31, 33, 52, 58, and 35 are associated with 95% of squamous-cell carcinomas of the cervix [17] . Both CaSki and ME-180 cells grow well in culture both as monolayers and as spheroids.
In our studies, we compared the response to Pc 4 PDT between monolayers and spheroids grown on Matrigel. Spheroids appear to be more representative of tumors in their response to therapeutic agents [18] . Further, the cervical cancer spheroids were placed on a matrigel:complete medium: 1:1 (v/v) foundation because cervical cancer appears to spread by local invasion to adjacent tissue structures and spheroids grown on extracellular matrix appear to be more representative of tumors [10] [18] . Tumors are better represented by spheroids because: morphology and proliferation rates are different than in monolayers; there is more phenotypic heterogeneity; gene expression is altered compared to monolayers and gradients for nutrients, catabolites, oxygen; and drugs exist and there are 3D tensional forces between cells [19] . In the case of both the CaSki and ME-180 spheroids, between 200 and 1000 µm in diameter, the growth rate was much slower than in the monolayers. Further, as expected, Pc 4 did not appear to be toxic to the CaSki or ME-180 spheroids and much higher concentrations of Pc 4 were required with the same laser dose to cause cytotoxicity in the tighter CaSki spheroids. The IC 50 for CaSki spheroids was 0.26 µM while the IC 50 for the ME-180 spheriods was 0.011 µM. This difference in response to Pc 4 PDT correlates with their 3D structures: the CaSki cells grown as spheroids were true spheres and very tightly compacted; the ME-180 spheroids were looser and grew in random 3D shapes. It was difficult to disrupt both types of spheroids with DMSO and other solvents; because of this, aqueous insoluble formazan crystals from the metabolism of MTT could not be completely extracted from CaSki nor ME-180 spheroids. The inability to extract the insoluble formazan crystals meant the assessment of the assays measuring cytotocity in the spheroids required microscopic imaging. in normal CD2F1 female mice [10] . Based on the data presented here and our data from previous studies with other xenograft models in mice [15] , we chose to apply the laser irradiation at 48 h after IV administration of Pc 4 at 2 mg/kg.
Our attempt at laser irradiation through the vaginal opening to treat the intracervical lesions was not successful. Although the mice survived the initial irradiation and the tumor appeared to be killed, four of the five mice with intracervical tumors, and one of two mice with subcutaneous tumors, had to be euthanized or died between two and five days after irradiation. It was apparent on necropsy that the irradiation had affected the small intestines as they were transparent and filled with black clots suggesting severe damage to the mucosal lining. We had considered the emptying time of the gastrointestinal tract of mice, (estimated at 6h in mice when the major route of elimination was through the feces [24] ) and had demonstrated that Pc 4 concentrations could not be detected in the colonic tissue past 24 h; we should have considered, however, the slow release and redistribution of Pc 4 from storage sites within other tissues. Most probably, Pc 4 was present in the contents of the gastrointestinal tract at high enough concentrations to result in injury and death of the mice when 75 J/cm 2 of irradiation at 670 nm was applied through the microfiber. In contrast, when the additional eight mice received Pc 4 PDT with transdermally applied laser irradiation, tumor volume was reduced and all mice survived. The delay in regrowth of xenografts suggests that additional irradiation could be applied at an interval of two weeks to prevent regrowth. Pc 4 has advantages over a number of other sensitizers as it is a defined compound with known spectra, while the spectra of tissue synthesized porphyrins after application of ALA or its related compounds are not known. Photofrin, Porfimer sodium, is a mix-ture of compounds as well, and has been used to treat CIN. Japanese studies have shown that colposcopic-assisted cervical canal illumination after intravenous Photofrin administration can achieve a high CR (<94%) [25] . [29] . We are encouraged therefore by the possibility of continuing these studies further in animals and eventually to women for the treatment cervical neoplasia. We feel the most clinically relevant application of Pc 4 PDT may be in its topical application in the treatment of CIN where light can be specifically directed at localized cervical lesions. The fact that PDT used in the treatment of CIN could potentially avoid the morbidity associated with current excisional or ablative techniques makes Pc 4 PDT worth investigating further. Pharmacokinetic studies would need to be performed in patients to identify the optimal drug dose for treatment of invasive cervical carcinoma due to the proximity of the lesion to vital organs. In addition, the application and dose of light would have to be focused more directly within the cervical lesion, either by direct application or interstitial therapy.
